RELATIVITY098
09 May 2022
RELATIVITY098
NCT05002569
A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)
Bristol-Myers Squibb
Cancer Type | Melanoma & other skin |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2021-10-19 |
Anticipated End Date | 2025-12-15 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Stella Papacharissiou |
stella.papacharissiou@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Dr Rachel Roberts-Thomson |
Recruitment Status | Not Yet Recruiting |
Keep up to date with the latest news and breakthroughs